EOLS Company Profile and Key Details

EOLS has shown weak momentum, losing -12.31% over the past week and -20.94% over the past quarter, though year-to-date performance is down -23.91%. Short-term trend indicators are bullishly aligned (SMA20 0.71%, SMA50 -16.72%, SMA200 -37.97%). The stock’s 14-day RSI is 42.53 (neutral), while the ATR of 0.23 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -69.95% below its high and over 9.75% above its low. Average 10-day trading volume of 634.03 thousand shares is below the 3-month average of 1.03 million, indicating normal recent market interest.

Evolus, Inc. has 64.69 million shares outstanding. The public float is 50.60 million shares, elevated short interest at 21.30% of float. This equals 13.48 million shares. The short ratio is 14.62 days. Institutional investors hold 103.29% of the float. Insiders own 11.81%. Alphaeon Corp holds 8.66 million shares, Alphaeon 1 LLC has 4.21 million shares and Medytox Inc. has 3.38 million shares. Over the past six months, insider transactions show net selling. They sold 12.80 thousand shares across 2 transactions.

Evolus, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.05. This means the shares are trading below this model’s fair value.

Evolus, Inc. generated EPS of -$0.91 over the past year. Five-year average earnings growth is 23.91%. The latest quarter delivered EPS of -$0.14. The next quarter is forecast at $0.03. Next year's EPS is expected at $17.67. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 11 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $27.00 to $13.00. The high target offers 553.75% upside. The low target suggests 214.77% downside. The mean target is $20.29. This offers 391.28% upside. Evolus, Inc. earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by -26.32%. The prior quarter beat by 166.67%. Over the last six quarters, Apple has recorded several small beats. These include 23.09% in July 31, 2024.

Evolus, Inc. (NASDAQ:EOLS) closed at $4.13 USD, losing -$0.16 (-3.73%) from the previous close of $4.29. The stock is currently trading near its 52-week low $4.09 and $14.60. With a market capitalization of about $267.71 million, Evolus, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.01). Key stats such as the average daily volume over the past year has been around 1.05 million shares, in line with its 52-week average. Headquartered in Newport Beach, CA, Evolus, Inc. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO David Moatazedi, the company employs approximately 372 people and listed since February 08, 2018. Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States.

Evolus, Inc. trades at a P/E ratio of -4.7, slightly below the S&P 500 average, with a price-to-sales ratio of 0.96 and a price-to-book ratio of -9.58 indicating negative book value, which may reflect financial stress. The P/FCF stands at -4.89, also below market averages.

Evolus, Inc. (NASDAQ:EOLS) shares are down -23.91% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Evolus, Inc. trading at a premium to the broader market with a P/E of -4.7. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $20.28, suggesting 391.04% upside. Our AI forecast model points to short-term strength (0.97% over two weeks), a medium-term fall (-31.96% over three months), and a longer-term loss (-59.81% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Evolus, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.97%, with price expected at $4.17 by March 17, 2026, within a range of $3.99 to $4.34 3-Month Outlook: Projected fall of -31.96%, reaching $2.81 by June 01, 2026, with a range of $1.99 to $3.28. 1-Year Outlook: Projected loss of -59.81%, with price at $1.66 by March 03, 2027, within a range of $0.00 to $0.00.